Information Provided By: 
Fly News Breaks for August 7, 2019
REGN
Aug 7, 2019 | 08:22 EDT
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $344 and kept his Market Perform rating after its Q2 results. The analyst notes that while earnings and revenues topped expectations with growth of Eylea and uptake of Dupixent looking "solid", he is concerned by the company's longer term outlook given the potential Eylea competition and the possibility of adverse Medicare Part B reform.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
